πŸ‡ΊπŸ‡Έ FDA
Patent

US 10519139

Polymorphs of Selinexor

granted A61KA61K31/497A61P

Quick answer

US patent 10519139 (Polymorphs of Selinexor) held by Karyopharm Therapeutics Inc. expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Karyopharm Therapeutics Inc.
Grant date
Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/497, A61P, A61P35/00